Axsome Therapeutics (AXSM) Stock Forecast & Price Target

Axsome Therapeutics is supported by Auvelity’s strong commercial momentum, with 2Q26 net product revenue of $180.3M rising 51% year over year, about 266,000 prescriptions, and new-to-brand prescriptions up 26% sequentially, while the recent ADA approval expands access to a larger, underserved market with favorable reimbursement. Its outlook is further strengthened by a clinically de-risked pipeline built largely on reformulations and repositioned compounds, which lowers development risk and supports multiple near-term catalysts, including AXS-12, AXS-14, and smoking-cessation data. With Sunosi and Symbravo adding incremental revenue, existing sales infrastructure already in place, and cash flow positivity modeled for 2027E, the company appears positioned for sustained fundamental growth.

Axsome Therapeutics is exposed to a highly concentrated revenue base, with performance overwhelmingly dependent on Auvelity while its other marketed and pipeline assets must still overcome commercialization, regulatory, and competitive hurdles. Growth in MDD is already decelerating from 46% in 3Q25 to 34% in 2Q26, prescriber breadth may be flattening at about 69,000 prescribers, and ADA faces cheap generic on/off-label use, lower persistence, and slower LTC rollout. The valuation case also carries material downside from GTN pressure, Medicare Part D and IRA-related exposure starting in 2032, and financing or dilution risk that can erode per-share value.